1Q22 Business Results

Key Business Performance RemsimaⓇ & InflectraⓇ Maintaining most prescribed Infliximab drug in Europe with the market share over 50% & continuously expanding prescriptions in Japan ✓ Achieved the market share three times higher than that of competitors led by additional listings at major US payers Market share of RemsimaⓇ in Europe and Japan Market share of InflectraⓇ in the US 23% 32% 42% 59% 57% 57% 56% 53% 53% 52% 52% 49% 12% 23% 28% 20% 19% 16% 12% 10% 8% 7% 5% 6% 4% 3% 1% 9% 8% 8% 7% 6% 4% 4% 3% 1% 0% 16.1Q 3Q 17.1Q 3Q 18.1Q 3Q 19.1Q 3Q 20.1Q 3Q 21.1Q 3Q '18 '19 120 '21 '22.03 Europe Note: market share is based on volume Source: IQVIA Japan Inflectra® " ■■A Biosimilar Note: market share is based on volume Source Symphony Health B Biosimilar Investor Relations 2022 8

View entire presentation